Given Imaging Pill Easy For Investors To Swallow In April: Stock Up 27%
This article was originally published in The Gray Sheet
Executive Summary
Given Imaging's first-quarter sales of M2A capsule endoscopy systems were ahead of expectations, leading to a 26.6% jump in the firm's stock price in April to $13.85
You may also be interested in...
Given Plans Software Upgrade On Camera Pill Workstation In Early 2003
Given Imaging is looking to upgrade the software on the entire installed base of its Given M2A camera pill computer workstations in the U.S. in the beginning of 2003
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”